Bracco Imaging Receives Regulatory Approval in China for SonoVue® in the Assessment of Fallopian Tube Patency
New indication of SonoVue® supports non-invasive assessment of female infertility through contrast-enhanced ultrasound in China MILAN, Aug. 6, 2025 /PRNewswire/ -- Bracco Imaging, a global leader in diagnostic imaging, today announced that its ultrasound contrast agent SonoVue® has been approved by the China's National Medical Products Administration (NMPA) for use in hysterosalpingo...
DeerRun Debuts 2 New Life-Changing Treadmills Designed to Transform Everyday Wellness
HOUSTON, Aug. 6, 2025 /PRNewswire/ -- DeerRun has recently introduced two new treadmill models to its growing portfolio of fitness equipment: the Z20 Suitcase Treadmill, a Muse Design Gold Award winner, and the X20, a high-performance treadmill featuring a 15% auto incline and DeerRun's first full-length running deck. DeerRun Debuts 2 New Life-Changing Treadmills Designed to Transform Everyday...
Sanyou Bio Wins the “2025 Best Customer Satisfaction CRO Award”
SHANGHAI, Aug. 5, 2025 /PRNewswire/ -- The highly anticipated 7th China Bio Innovation Expo was recently held in grand fashion in Suzhou. At the awards ceremony on August 1, Sanyou Bio was honored with the "2025 Best Customer Satisfaction CRO Award" in recognition of its deep expertise and outstanding performance in the field of preclinical research for new drug development....
Seegene Unveils CURECA™ and STAgora™ at ADLM 2025, Advancing the Next Stage of Diagnostics
Dr. Jong-Yoon Chun, Chairman and CEO of Seegene, highlights progress toward fully automated and data-driven molecular testing Introduction of CURECA™, the first fully unattended PCR automation system, and STAgora™, a real-time global data analytics platform Technologies designed to scale automation, enhance data insights, and support the company's long-term vision of...
FigureLabs: World’s First AI scientific illustration tool for Effortless Publication Figures
OXFORD, United Kingdom, Aug. 5, 2025 /PRNewswire/ -- FigureLabs, the world's first fully AI-driven scientific illustration tool, has officially launched, marking a significant advancement for researchers worldwide. Designed to streamline the creation of publication-quality figures, FigureLabs saves time and enhances the clarity and impact of scientific work. With four core features—Sketch-to-Figure, Text-to-Figure, Figure Refiner, and Image Vectorization—the tool simplifies workflows...
BON Announces Reciept of Nasdaq Compliance Letter
XI'AN, China, Aug. 5, 2025 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or "the Company"), a leading provider of bio-ingredient solutions for the natural health and personal care industries, today announced reciept of compliance notification from the Nasdaq Stock Market LLC. As previously reported on a Form 6-K filed with the U.S. Securities and Exchange Commission on...
Court Sides with Cardiovalve in Edwards patent spat
HANGZHOU, China, Aug. 5, 2025 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. ("Venus Medtech", Stock Code: 02500.HK) recently announced a decisive legal victory for its wholly-owned subsidiary Cardiovalve Ltd. ("Cardiovalve") against Edwards Lifesciences Corporation and Edwards Lifesciences LLC. (collectively "Edwards"). The United States Court of Appeals for the Federal Circuit ("CAFC") has formally issued its mandate in Case 23-1515,...
iNtRON Bio, Demonstrated Toxin-Neutralizing Effect of IMPA™ Phage Engineering Technology in Colorectal Cancer Model and Completed the US Patent Application
• Successful validation of payloaded anti-colibactin toxin phage using IMPA™ technology • Demonstrated 'Dual-target Therapeutic Strategy' by bacterial eradication and toxin neutralization • Filed the US patent application for the candidate substance and preclinical studies including PoC underway BOSTON and SEOUL, South Korea, Aug. 5, 2025 /PRNewswire/ -- Recently, a specific genotype of E. coli that may cause colorectal cancer has...
Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Small Molecule Oral GLP-1R Agonist, ASC30, in Participants with Obesity or Overweight
- 13-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of two oral formulations of ASC30, a once-daily tablet, in 125 participants with obesity or overweight. - All 125 participants enrolled in just over one month; topline data expected in the fourth quarter of 2025. HONG KONG, Aug. 5, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672,...
SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes
BOSTON and ROLLE, Switzerland, Aug. 5, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an expansion of its partnership with AstraZeneca (LSE/STO/Nasdaq: AZN). This new, multi-year collaboration will leverage SOPHiA GENETICS's multimodal AI Factories to generate evidence on the...
